Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 43


Nuclear GSK3β promotes tumorigenesis by phosphorylating KDM1A and inducing its deubiquitylation by USP22.

Zhou A, Lin K, Zhang S, Chen Y, Zhang N, Xue J, Wang Z, Aldape KD, Xie K, Woodgett JR, Huang S.

Nat Cell Biol. 2016 Sep;18(9):954-966. doi: 10.1038/ncb3396. Epub 2016 Aug 8.


GSK3β inactivation promotes the oncogenic functions of EZH2 and enhances methylation of H3K27 in human breast cancers.

Ko HW, Lee HH, Huo L, Xia W, Yang CC, Hsu JL, Li LY, Lai CC, Chan LC, Cheng CC, Labaff AM, Liao HW, Lim SO, Li CW, Wei Y, Nie L, Yamaguchi H, Hung MC.

Oncotarget. 2016 Aug 30;7(35):57131-57144. doi: 10.18632/oncotarget.11008.


Local anesthetic bupivacaine induced ovarian and prostate cancer apoptotic cell death and underlying mechanisms in vitro.

Xuan W, Zhao H, Hankin J, Chen L, Yao S, Ma D.

Sci Rep. 2016 May 19;6:26277. doi: 10.1038/srep26277.


Regulation of mitochondrial functions by protein phosphorylation and dephosphorylation.

Lim S, Smith KR, Lim ST, Tian R, Lu J, Tan M.

Cell Biosci. 2016 Apr 14;6:25. doi: 10.1186/s13578-016-0089-3. eCollection 2016. Review.


GSK-3α Is a Novel Target of CREB and CREB-GSK-3α Signaling Participates in Cell Viability in Lung Cancer.

Park SA, Lee JW, Herbst RS, Koo JS.

PLoS One. 2016 Apr 6;11(4):e0153075. doi: 10.1371/journal.pone.0153075. eCollection 2016.


MicroRNA-1229 overexpression promotes cell proliferation and tumorigenicity and activates Wnt/β-catenin signaling in breast cancer.

Tan Z, Zheng H, Liu X, Zhang W, Zhu J, Wu G, Cao L, Song J, Wu S, Song L, Li J.

Oncotarget. 2016 Apr 26;7(17):24076-87. doi: 10.18632/oncotarget.8119.


Glycogen Synthase Kinase-3 (GSK-3)-Targeted Therapy and Imaging.

Pandey MK, DeGrado TR.

Theranostics. 2016 Feb 17;6(4):571-93. doi: 10.7150/thno.14334. eCollection 2016. Review.


MST3 promotes proliferation and tumorigenicity through the VAV2/Rac1 signal axis in breast cancer.

Cho CY, Lee KT, Chen WC, Wang CY, Chang YS, Huang HL, Hsu HP, Yen MC, Lai MZ, Lai MD.

Oncotarget. 2016 Mar 22;7(12):14586-604. doi: 10.18632/oncotarget.7542.


Nimbolide, a neem limonoid inhibits Phosphatidyl Inositol-3 Kinase to activate Glycogen Synthase Kinase-3β in a hamster model of oral oncogenesis.

Sophia J, Kiran Kishore T K, Kowshik J, Mishra R, Nagini S.

Sci Rep. 2016 Feb 23;6:22192. doi: 10.1038/srep22192.


GSK-3β regulates tumor growth and angiogenesis in human glioma cells.

Zhao P, Li Q, Shi Z, Li C, Wang L, Liu X, Jiang C, Qian X, You Y, Liu N, Liu LZ, Ding L, Jiang BH.

Oncotarget. 2015 Oct 13;6(31):31901-15. doi: 10.18632/oncotarget.5043.


Loss of GSK-3 Causes Abnormal Astrogenesis and Behavior in Mice.

Jung EM, Ka M, Kim WY.

Mol Neurobiol. 2016 Aug;53(6):3954-3966. doi: 10.1007/s12035-015-9326-8. Epub 2015 Jul 17.


Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases.

Beurel E, Grieco SF, Jope RS.

Pharmacol Ther. 2015 Apr;148:114-31. doi: 10.1016/j.pharmthera.2014.11.016. Epub 2014 Nov 27. Review.


GSK-3 modulates cellular responses to a broad spectrum of kinase inhibitors.

Thorne CA, Wichaidit C, Coster AD, Posner BA, Wu LF, Altschuler SJ.

Nat Chem Biol. 2015 Jan;11(1):58-63. doi: 10.1038/nchembio.1690. Epub 2014 Nov 17.


CDK5 activator protein p25 preferentially binds and activates GSK3β.

Chow HM, Guo D, Zhou JC, Zhang GY, Li HF, Herrup K, Zhang J.

Proc Natl Acad Sci U S A. 2014 Nov 11;111(45):E4887-95. doi: 10.1073/pnas.1402627111. Epub 2014 Oct 20. Erratum in: Proc Natl Acad Sci U S A. 2015 Jun 23;112(25):E3313.


Glycogen synthase kinase 3 regulates cell death and survival signaling in tumor cells under redox stress.

Venè R, Cardinali B, Arena G, Ferrari N, Benelli R, Minghelli S, Poggi A, Noonan DM, Albini A, Tosetti F.

Neoplasia. 2014 Sep;16(9):710-22. doi: 10.1016/j.neo.2014.07.012.


Analysis of tumor suppressor genes based on gene ontology and the KEGG pathway.

Yang J, Chen L, Kong X, Huang T, Cai YD.

PLoS One. 2014 Sep 10;9(9):e107202. doi: 10.1371/journal.pone.0107202. eCollection 2014.


GSK3 protein positively regulates type I insulin-like growth factor receptor through forkhead transcription factors FOXO1/3/4.

Huo X, Liu S, Shao T, Hua H, Kong Q, Wang J, Luo T, Jiang Y.

J Biol Chem. 2014 Sep 5;289(36):24759-70. doi: 10.1074/jbc.M114.580738. Epub 2014 Jul 22.


GSK-3 as potential target for therapeutic intervention in cancer.

McCubrey JA, Steelman LS, Bertrand FE, Davis NM, Sokolosky M, Abrams SL, Montalto G, D'Assoro AB, Libra M, Nicoletti F, Maestro R, Basecke J, Rakus D, Gizak A, Demidenko ZN, Cocco L, Martelli AM, Cervello M.

Oncotarget. 2014 May 30;5(10):2881-911. Review.


GSK-3β: a key regulator of breast cancer drug resistance.

Martelli AM, Buontempo F, Evangelisti C.

Cell Cycle. 2014;13(5):697-8. doi: 10.4161/cc.28091. Epub 2014 Feb 4. No abstract available.


Delayed administration of a single dose of lithium promotes recovery from AKI.

Bao H, Ge Y, Wang Z, Zhuang S, Dworkin L, Peng A, Gong R.

J Am Soc Nephrol. 2014 Mar;25(3):488-500. doi: 10.1681/ASN.2013040350. Epub 2014 Jan 9.

Supplemental Content

Support Center